135 related articles for article (PubMed ID: 22896002)
1. Clinical and prognostic implications of low or high level of von Willebrand factor in patients with Waldenstrom macroglobulinemia.
Hivert B; Caron C; Petit S; Charpy C; Fankam-Siaka C; Lecocq S; Zawadzki C; Susen S; Rusu M; Duhamel A; Tournilhac O; Goudemand J; Morel P
Blood; 2012 Oct; 120(16):3214-21. PubMed ID: 22896002
[TBL] [Abstract][Full Text] [Related]
2. Elevated vWF Antigen Serum Levels Are Associated With Poor Prognosis, and Decreased Circulating ADAMTS-13 Antigen Levels Are Associated With Increased IgM Levels and Features of WM but not Increased vWF Levels in Patients With Symptomatic WM.
Gavriatopoulou M; Terpos E; Ntanasis-Stathopoulos I; Papasotiriou I; Fotiou D; Migkou M; Roussou M; Kanellias N; Ziogas D; Dialoupi I; Eleutherakis Papaiakovou E; Kastritis E; Dimopoulos MA
Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):23-28. PubMed ID: 30224328
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Von Willebrand factor (VWF) activity VWF:Ac with VWF ristocetin cofactor activity VWF:RCo.
Geisen U; Zieger B; Nakamura L; Weis A; Heinz J; Michiels JJ; Heilmann C
Thromb Res; 2014 Aug; 134(2):246-50. PubMed ID: 24891215
[TBL] [Abstract][Full Text] [Related]
4. A two-centre comparative evaluation of new automated assays for von Willebrand factor ristocetin cofactor activity and antigen.
Stufano F; Lawrie AS; La Marca S; Berbenni C; Baronciani L; Peyvandi F
Haemophilia; 2014 Jan; 20(1):147-53. PubMed ID: 24028703
[TBL] [Abstract][Full Text] [Related]
5. VWF, WM, and angiogenesis: is there a link?
Kastritis E; Dimopoulos MA
Blood; 2012 Oct; 120(16):3163-4. PubMed ID: 23086619
[No Abstract] [Full Text] [Related]
6. Correlation between von Willebrand factor antigen, von Willebrand factor ristocetin cofactor activity and factor VIII activity in plasma.
Lippi G; Franchini M; Salvagno GL; Montagnana M; Poli G; Guidi GC
J Thromb Thrombolysis; 2008 Oct; 26(2):150-3. PubMed ID: 17786534
[TBL] [Abstract][Full Text] [Related]
7. von Willebrand factor Ristocetin co-factor activity to von Willebrand factor antigen level ratio for diagnosis of acquired von Willebrand syndrome caused by aortic stenosis.
Okubo N; Sugawara S; Fujiwara T; Sakatsume K; Doman T; Yamashita M; Goto K; Tateishi M; Suzuki M; Shirakawa R; Eura Y; Kokame K; Hayakawa M; Matsumoto M; Kawate Y; Miura M; Takiguchi H; Soga Y; Shirai S; Ando K; Arai Y; Nakayoshi T; Fukumoto Y; Takahama H; Yasuda S; Tamura T; Watanabe S; Kimura T; Yaoita N; Shimokawa H; Saiki Y; Kaikita K; Tsujita K; Yoshii S; Nakase H; Fujimaki SI; Horiuchi H
Res Pract Thromb Haemost; 2024 Jan; 8(1):102284. PubMed ID: 38268521
[TBL] [Abstract][Full Text] [Related]
8. Acquired Von Willebrand syndrome in patients on long-term support with HeartMate II.
Heilmann C; Trummer G; Beyersdorf F; Brehm K; Berchtold-Herz M; Schelling J; Geisen U; Zieger B
Eur J Cardiothorac Surg; 2017 Mar; 51(3):587-590. PubMed ID: 28082469
[TBL] [Abstract][Full Text] [Related]
9. Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P).
Michiels JJ; Berneman ZN; van der Planken M; Schroyens W; Budde U; van Vliet HH
Blood Coagul Fibrinolysis; 2004 Jun; 15(4):323-30. PubMed ID: 15166918
[TBL] [Abstract][Full Text] [Related]
10. Influence of ABO blood group on von Willebrand factor tests in healthy Saudi blood donors.
Alharbi A; Hassan SB; Al-Momen AK; Al-Saleh K; Nasr R; Kohgear H; Owaidah T
Blood Coagul Fibrinolysis; 2018 Mar; 29(2):211-215. PubMed ID: 29369083
[TBL] [Abstract][Full Text] [Related]
11. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.
Michiels JJ; van de Velde A; van Vliet HH; van der Planken M; Schroyens W; Berneman Z
Semin Thromb Hemost; 2002 Apr; 28(2):111-32. PubMed ID: 11992235
[TBL] [Abstract][Full Text] [Related]
12. Validation of a new panel of automated chemiluminescence assays for von Willebrand factor antigen and activity in the screening for von Willebrand disease.
Verfaillie CJ; De Witte E; Devreese KM
Int J Lab Hematol; 2013 Oct; 35(5):555-65. PubMed ID: 23551532
[TBL] [Abstract][Full Text] [Related]
13. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
[TBL] [Abstract][Full Text] [Related]
14. Desmopressin therapy to assist the functional identification and characterisation of von Willebrand disease: differential utility from combining two (VWF:CB and VWF:RCo) von Willebrand factor activity assays?
Favaloro EJ; Thom J; Patterson D; Just S; Dixon T; Koutts J; Baccala M; Rowell J; Baker R
Thromb Res; 2009 Apr; 123(6):862-8. PubMed ID: 19064279
[TBL] [Abstract][Full Text] [Related]
15. Extracorporeal membrane oxygenation induces short-term loss of high-molecular-weight von Willebrand factor multimers.
Tauber H; Ott H; Streif W; Weigel G; Loacker L; Fritz J; Heinz A; Velik-Salchner C
Anesth Analg; 2015 Apr; 120(4):730-6. PubMed ID: 25565317
[TBL] [Abstract][Full Text] [Related]
16. High resolution multimer analysis and the PFA-100 platelet function analyser can detect von Willebrand disease type 2A without a pathological ratio of ristocetin cofactor activity and von Willebrand antigen level.
Weiss DR; Strasser EF; Ringwald J; Zimmermann R; Eckstein R
Clin Lab; 2012; 58(11-12):1203-9. PubMed ID: 23289190
[TBL] [Abstract][Full Text] [Related]
17. Content and functional activity of von Willebrand factor in apheresis plasma.
Burnouf T; Caron C; Burkhardt T; Goudemand J
Vox Sang; 2004 Jul; 87(1):27-33. PubMed ID: 15260819
[TBL] [Abstract][Full Text] [Related]
18. Levels and activities of von Willebrand factor and metalloproteinase with thrombospondin type-1 motif, number 13 in inflammatory bowel diseases.
Cibor D; Owczarek D; Butenas S; Salapa K; Mach T; Undas A
World J Gastroenterol; 2017 Jul; 23(26):4796-4805. PubMed ID: 28765701
[TBL] [Abstract][Full Text] [Related]
19. Laboratory Testing for von Willebrand Factor Ristocetin Cofactor (VWF:RCo).
Mohammed S; Favaloro EJ
Methods Mol Biol; 2017; 1646():435-451. PubMed ID: 28804846
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.
Favaloro EJ; Lloyd J; Rowell J; Baker R; Rickard K; Kershaw G; Street A; Scarff K; Barrese G; Maher D; McLachlan AJ
Thromb Haemost; 2007 Jun; 97(6):922-30. PubMed ID: 17549293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
